Filing Details

Accession Number:
0000899243-22-034125
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-25 16:31:01
Reporting Period:
2022-10-21
Accepted Time:
2022-10-25 16:31:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733257 Finch Therapeutics Group Inc. FNCH Biological Products, (No Disgnostic Substances) (2836) 823433558
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1880032 Marc Blaustein C/O Finch Therapeutics Group, Inc.
200 Inner Belt Road, Suite 400
Somerville MA 02143
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-10-21 3,636 $1.39 32,614 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
  2. Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.